| 前收盘价格 | 1.38 |
| 成交量 | 11,032 |
| 价格/销量 (P/S) | 1.12 |
| 股市价格/股市净资产 (P/B) | 9.89 |
| 52周波幅 |
| 营业毛利率 | -106.77% |
| 营业利益率 (TTM) | -52.24% |
| 稀释每股收益 (EPS TTM) | -2.64 |
| 季度收入增长率 (YOY) | 49.70% |
| 季度盈利增长率 (YOY) | -60.90% |
| 总债务/股东权益 (D/E MRQ) | 778.95% |
| 流动比率 (MRQ) | 0.380 |
| 营业现金流 (OCF TTM) | -6.40 M |
| 杠杆自由现金流 (LFCF TTM) | 10.32 M |
| 资产报酬率 (ROA TTM) | -17.42% |
| 股东权益报酬率 (ROE TTM) | -232.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Celularity Inc. | 混合的 | 混合的 |
AIStockmoo 评分
-0.1
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 5.0 |
| 平均 | -0.13 |
|
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 51.26% |
| 机构持股比例 | 14.66% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| C V Starr & Co Inc | 30 Jun 2026 | 764,069 |
| Biltmore Family Office, Llc | 30 Jun 2026 | 35,000 |
| Keynote Financial Services Llc | 30 Jun 2026 | 29,920 |
| Centerstar Asset Management, Llc | 30 Jun 2026 | 21,000 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合